| Document |
Document Title |
|
WO/2002/017895A2 |
Aldosterone receptor antagonists for the prevention and treatment of cognitive dysfunction are disclosed.
|
|
WO/2002/010188A1 |
The invention makes a 16$g(a)-substituted steroidal compound available having formula 1, wherein the dotted ring is a fully saturated, a fully aromatic or a saturated ring with a $g(D)5-10 double bond; R?1¿ is (C¿1?-C¿3?)alkyl or (C¿...
|
|
WO/2002/004410A1 |
A process for producing a sulfamate compound which comprises reacting a hydroxylated compound with sulfamoyl chloride, characterized in that the reaction is conducted in the presence of a compound such as N,N-dimethylacetamide or 1-methy...
|
|
WO/2002/000679A2 |
Compounds of formula (I), where R is a monovalent cyclic organic group having from 3 to 15 atoms in the ring system, useful as pharmaceuticals.
|
|
WO/2001/098322A1 |
The present invention comprises the design, synthesis and development of a new class of chemotherapeutic agents for prophylactic and therapeutic treatments in a mammal, particularly a human, believed to be at risk of suffering from a hor...
|
|
WO/2001/085174A1 |
The invention discloses formulations for administration through pressurized metered dose inhalers containing as active ingredient a glucocorticoid, in particular the (22R) epimer of budesonide, in solution in a hydrofluorocarbon propella...
|
|
WO/2001/083512A1 |
A compound of formula (I) and pharmaceutical acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolation or in mixture, wherein, independently at each occurrence: R?1¿ and R?2¿ are selected from hydrogen, oxygen so as ...
|
|
WO/2001/074839A2 |
Methods of using 7$g(a),11$g(b)-dimethyl-17$g(b)-hydroxy-4-estren-3-one bucyclate (I) and 7$g(a),11$g(b)-dimethyl-17$g(b)-hydroxyestr-4-en-3-one 17-undecanoate (II) for various hormonal therapies, dosage forms comprising 7$g(a),11$g(b)-d...
|
|
WO/2001/070760A1 |
An improved process and composition are dislcosed for isolation of steroids containing a 5,7-diene functionality from a sterol mixture that comprises formation of a Diels-Alder reaction product of the ster-5,7-dienol in the presence of a...
|
|
WO/2001/062771A1 |
The present invention relates to pharmaceutically active steroid derivatives with an additional ring annulated to ring A, to pharmaceutical compositions comprising and to the use of these compounds for the preparation of medicaments. Mor...
|
|
WO/2001/056578A1 |
The invention provides the use of rofleponide, its esters and salts in the manufacture of a medicament for use in the treatment of irritable bowel syndrome (IBS) and a pharmaceutical formulation for use in such treatment.
|
|
WO/2001/056577A1 |
A method of increasing alertness in an individual by administering an effective amount of an alertness-increasing vomeropherin to the individual; and an alarm device that, when activated, emits an alertness-increasing vomeropherin. The m...
|
|
WO/2001/055122A1 |
. The invention concerns compounds of general formula (I) wherein: R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. Said compounds are useful in the treatment of pathologies related to the insulin-resistance syndrome.
|
|
WO/2001/052856A2 |
The invention concerns the use of at least a compound selected in the group consisting of dehydroepiandrosterone, its chemical precursors, its chemical derivatives, its biological precursors and metabolic derivatives, for preparing a com...
|
|
WO/2001/053321A2 |
Use of a compound of formula (I) or a 3-enol C¿1? ¿to? ¿4? alkanoate ester thereof in the manufacture of a medicament for the treatment of a hormone dependant condition by modulation of the oestrogen receptor $g(b) (ER$g(b)) wherein R...
|
|
WO/2001/049703A2 |
The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.
|
|
WO/2001/047945A1 |
The present invention provides a process for preparing the antiprogestational agent, 17$g(a)-acetoxy-11$g(b)-[4-N,N-(dimethylamino)phenyl]-21-met
hoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes ...
|
|
WO/2001/040256A1 |
The invention relates to natural compounds of formula (I) some of which are to processes for obtaining and preparing them, to derivatives of these natural compounds, and to their use for controlling animal pests in which R?6¿ and R?7¿ ...
|
|
WO/2001/040253A2 |
The invention concerns a 3-methylene steroid derivative having general formula (1) wherein R?1¿ is H or together with R?3¿ forms a $g(b)-epoxide or R?1¿ is absent if there is a 5-10 or 4-5 double bond; R?2¿ is (C¿1?-C¿5?)alkyl or C...
|
|
WO/2001/034132A2 |
The present invention provides methods of treating, inhibiting or preventing pathogenic change resulting from vascular injury in a subject, particularly restenosis resulting substantially from angioplasty. The methods comprise administer...
|
|
WO/2001/029036A2 |
An allosteric site on muscarinic receptors is disclosed, together with its use for screening for compounds capable of modulating the binding of a primary ligand such as acetylcholine to the receptor. The site is characterised herein a se...
|
|
WO/2001/023408A1 |
The invention discloses the use of 5-hydroxysapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.
|
|
WO/2001/023406A1 |
The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.
|
|
WO/2001/023407A1 |
The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.
|
|
WO/2001/018027A1 |
Disclosed are novel, selective estrogens type having a steroid skeleton with a non-aromatic A-ring and a free or capped hydroxyl group at carbon atom No. 3. The estrogens satisfy general formula (I), in which R?1¿ is H, (C¿1?-C¿3?)alk...
|
|
WO/2000/071563A2 |
In accordance with the present invention, there have been identified extracts from a tropical plant that initiate paclitaxel-like microtubule bundling. Bioassay-directed purification yields the steroid taccalonolide A. Taccalonolide, lik...
|
|
WO/2000/067801A2 |
The present invention relates to the field of prodrugs of chemotherapeutic agents and method of use thereof.
|
|
WO/2000/066612A1 |
Androgen glycosides provide free, circulatory androgen on oral administration as they are subject to less, first pass breakdown by the liver.
|
|
WO/2000/064882A2 |
An improved process for the preparation of single enantiomers of formula (I), and novel intermediates and processes thereto.
|
|
WO/2000/059922A1 |
The invention relates to novel equilenine derivatives of general formula (I) and methods for producing the same and medicaments containing said derivatives. The novel compounds are potent antioxidants and are used in the geriatric prophy...
|
|
WO/2000/056759A1 |
Steroid derivatives useful as the intermediate for preparing vitamin D derivatives such as 1$g(a), 25-dihydroxyvitamin D¿3? and 2$g(b)-(3-hydroxypropoxy)-1$g(a), 25-dihydroxyvitamin D¿3?, i.e., halides of general formula (II) (wherein ...
|
|
WO/2000/054780A2 |
A unit dose formulation comprising 0.25 to 2 mg of a corticosteroid. This small dose can be used to treat rheumatoid arthritis, especially if adapted to release at least 90 % by weight of the corticosteroid, 2 to 8 hours after administra...
|
|
WO/2000/043408A2 |
Novel sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and...
|
|
WO2000011017A9 |
The invention relates to synthetic Na<+>/K<+>-ATPase inhibitory factors, compositions and dosage forms comprising them, and methods of their preparation and use. Specific inhibitory factors of the invention include borate and phosphate c...
|
|
WO/2000/002564A1 |
This invention relates to the prophylaxis of choroidal neovascularisation in macular degeneration by the introduction of a suitable anti-inflammatory agent into the vitreous. In particular, it relates to the prophylaxis of neovascularisa...
|
|
WO/1999/067272A1 |
The present invention provides a new bioactive compound of formula (I), which has an antimicrobial activity against pathogenic microorganisms, and a process for production thereof. Also provided are a pharmaceutical composition comprisin...
|
|
WO/1999/052534A1 |
The present invention makes available assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein or aberrant activation of a hedgehog signal transduction pathway, e.g., which involve the use of a ste...
|
|
WO/1999/048507A2 |
The invention discloses the use of a number of saponins and sapogenins, notably those of steroidal structure, in the treatment of cognitive disfunction and similar conditions. Methods of treatment, and pharmaceutical compositions are als...
|
|
WO/1999/048482A2 |
The invention discloses the use of a smilagenin and anzurogenin-D in the treatment of cognitive disfunction and similar conditions. Methods of treatment, and pharmaceutical compositions are also disclosed.
|
|
WO/1999/047144A1 |
The invention provides the use of a glucocorticoid having a first pass metabolism in the liver of at least 90 % as active substance, for the manufacturing of a medicament for oral or rectal administration in the treatment of glomerulonep...
|
|
WO/1999/035161A1 |
A process for producing a compound of formula (I) wherein the dotted lines --- independently represent a single or double bond and R, R¿1?, R¿2? and R¿3? are each hydrogen or an organic radical, comprises treating the corresponding 17...
|
|
WO/1999/034806A1 |
This invention provides novel compounds derived from a marine sponge, $i(Adocia sp.), that specifically modulate kinesin activity by targeting the kinesin motor domain and mimicking the activity of a microtubule. The compounds act as pot...
|
|
WO/1999/028336A1 |
16$g(a),17$g(a)-Dialkylated steroids are prepared by reacting a 16$g(a)-alkyl-17(20)-enyl-20-silyl ether with an alkylating agent and an enol silyl ether cleaving agent in a suitable solvent.
|
|
WO/1999/025359A1 |
The invention provides a process for the sterilization of a powdered form of a glucocorticosteroid, sterile glucocorticosteroids, sterile formulations containing glucocorticosteroids and use thereof in the treatment of an allergic and/or...
|
|
WO/1999/016449A1 |
The present invention relates to Ca?2+¿ channel blockers and more particularly to the R-type Ca?2+¿ channel blockers. More specifically, the invention relates to Ca?2+¿ channel blockers activity of $i(Mandevilla velutina) and $i(Mande...
|
|
WO/1999/001467A2 |
There are described therapeutically active compounds or salts or solvates thereof, hydrolysable in human or animal blood to compounds with reduced therapeutic activity. There is also described a method of identifying a compound capable o...
|
|
WO/1998/052542A1 |
A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including the anti-inflammatory drug ciclesonide, hydrofluorocarbon propellants such as HFC 134a and/or 227, and ethanol in an amount sufficient to solubilize...
|
|
WO/1998/050419A2 |
Novel 4-aza-steroid compounds are provided, which have functional groups at one or more of positions 7, 11 and 15, such as hydroxyl or hydroxyl derivative groups. The compounds are active against 5-$g(a)-reductase giving indications of u...
|
|
WO/1998/046243A2 |
A pharmaceutical composition contains an extract obtainable from a plant of the genus $i(Trichocaulon) or $i(Hoodia) containing an appetite suppressant agent having the formula (1). A process for obtaining the extract and a process for s...
|
|
WO/1998/042729A2 |
The invention relates to novel estratrienes of general formula (I) containing several sulfamoyoxy groups per molecule (m = 1-5). They are produced by reacting the appropriate steroid alcohols with sulfamoy or n-alkyl or alkanoylsulfamoyl...
|
